Celularity Inc. has announced an exclusive collaboration with Vesalius Longevity Labs to enhance the manufacturing of peptide active pharmaceutical ingredients (APIs) in the United States. This partnership, revealed in a press release on October 29, 2026, is significant as it combines Celularity's manufacturing capabilities with Vesalius's Peptual platform.

The collaboration aims to establish a strong domestic supply chain for peptide APIs, ensuring consistent product quality and lot-level traceability. This move is in line with current good manufacturing practice standards and is set to take place at Celularity's facility in New Jersey.

“The collaboration pairs Celularity’s manufacturing infrastructure and technical expertise with Vesalius’s Peptual platform,” the filing stated. “The parties intend to establish a domestic supply platform that supports consistent product quality and lot-level traceability while strengthening the resilience and accountability of the peptide API supply chain.”

Celularity, classified under the SIC code 2834 for Pharmaceutical Preparations, is positioning itself strategically within the industry. The partnership is expected to bolster its capabilities in the competitive pharmaceutical market, where companies are increasingly focusing on local production to enhance reliability and reduce supply chain risks.

As a smaller reporting company, Celularity's collaboration with Vesalius could set a precedent for other firms in the pharmaceutical sector, potentially influencing how they approach manufacturing and supply chain management. The partnership may also prompt competitors to rethink their strategies as the industry evolves towards more localized production.

Looking ahead, the filing does not specify what happens next, but the collaboration is expected to unfold as both companies work to implement their plans for U.S.-based peptide API production.